Diabetes, Obesity and Metabolism
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
Effect of caloric restriction with and without exercise training on oxidative stress and endothelial function in obese subjects with type 2 diabetes
Diabetes, Obesity and Metabolism - Tập 10 Số 11 - Trang 1062-1073 - 2008
Aim: Effects of dietary weight loss on endothelial function, particularly when
combined with exercise training, is largely unknown in type 2 diabetes. We
sought to determine whether aerobic exercise training provided any additional
improvements in endothelial function, oxidative stress or other established
markers of cardiovascular risk when combined with an energy‐restricted diet in
patients wit...
Effects of an energy‐restricted low‐carbohydrate, high unsaturated fat/low saturated fat diet versus a high‐carbohydrate, low‐fat diet in type 2 diabetes: A 2‐year randomized clinical trial
Diabetes, Obesity and Metabolism - Tập 20 Số 4 - Trang 858-871 - 2018
AimTo examine whether a low‐carbohydrate, high‐unsaturated/low‐saturated fat
diet (LC) improves glycaemic control and cardiovascular disease (CVD) risk
factors in overweight and obese patients with type 2 diabetes (T2D).MethodsA
total of 115 adults with T2D (mean [SD]; BMI, 34.6 [4.3] kg/m2; age, 58 [7]
years; HbA1c, 7.3 [1.1]%) were randomized to 1 of 2 planned energy‐matched,
hypocaloric diets c...
Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes
Diabetes, Obesity and Metabolism - Tập 15 Số 2 - Trang 189-191 - 2013
Pharmacogenetic studies revealed that variants in genes related to the
pharmacokinetics of metformin were associated with glucose‐lowering effect of
metformin. The aim of this study was to investigate possible associations of the
variants in genes encoding organic cationic transporters–solute carrier family
22, members A1, A2 (SLC22A1, SLC22A2) and solute carrier family 47, member A1
(SLC47A1) wit...
Metabolic effects of L actobacillus reuteriDSM 17938 in people with type 2 diabetes: A randomized controlled trial
Diabetes, Obesity and Metabolism - Tập 19 Số 4 - Trang 579-589 - 2017
AimsTo investigate the metabolic effects of 12‐week oral supplementation with
Lactobacillus reuteri DSM 17938 in patients with type 2 diabetes on insulin
therapy.Materials and methodsIn a double‐blind trial, we randomized 46 people
with type 2 diabetes to placebo or a low (108 CFU/d) or high dose (1010 CFU/d)
of L. reuteri DSM 17938 for 12 weeks. The primary endpoint was the effect of
supplementat...
Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro
Diabetes, Obesity and Metabolism - Tập 20 Số 9 - Trang 2264-2273 - 2018
AimsTo test the hypothesis that brown adipose tissue (BAT) is a metformin target
tissue by investigating in vivo uptake of [11C]‐metformin tracer in mice and
studying in vitro effects of metformin on cultured human brown
adipocytes.Materials and methodsTissue‐specific uptake of metformin was assessed
in mice by PET/CT imaging after injection of [11C]‐metformin. Human brown
adipose tissue was obtai...
Treatment with LY 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes
Diabetes, Obesity and Metabolism - Tập 19 Số 11 - Trang 1521-1528 - 2017
AimsTo evaluate whether treatment with LY2409021, a novel, selective glucagon
receptor antagonist, is associated with changes in hepatic fat and other safety
variables related to the benefit–risk profile for chronic use in patients with
type 2 diabetes (T2D).MethodsSafety and efficacy were assessed in patients with
T2D taking metformin and sulphonylurea who were randomized to LY2409021 20 mg
(n = ...
Physiologic action of glucagon on liver glucose metabolism
Diabetes, Obesity and Metabolism - Tập 13 Số s1 - Trang 118-125 - 2011
Glucagon is a primary regulator of hepatic glucose production (HGP) in vivo
during fasting, exercise and hypoglycaemia. Glucagon also plays a role in
limiting hepatic glucose uptake and producing the hyperglycaemic phenotype
associated with insulin deficiency and insulin resistance. In response to a
physiological rise in glucagon, HGP is rapidly stimulated. This increase in HGP
is entirely attribu...
Diabetes, Obesity and Metabolism - Tập 23 Số 9 - Trang 2125-2136 - 2021
AbstractAimTo determine the overall efficacy of high‐ versus low‐dose
sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors in patients with type 2
diabetes (T2D).Material and MethodsA literature search using MEDLINE, EMBASE and
the Cochrane Library was performed from 1 January 2006 to 23 September 2020.
Random effects models were used to calculate mean differences (MDs) and pooled
relative risk (RR)...
Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
Diabetes, Obesity and Metabolism - Tập 19 Số 3 - Trang 436-441 - 2017
Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved
for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and
III trials in people with T2D (N = 6005) were used to evaluate the effects of
dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney
Disease Epidemiology Collaboration]), urine albumin‐to‐creatinine ratio (UACR)
and kidney...
Do we know the true mechanism of action of the DPP ‐4 inhibitors?
Diabetes, Obesity and Metabolism - Tập 20 Số 1 - Trang 34-41 - 2018
The prevalence of type 2 diabetes is increasing, which is alarming because of
its serious complications. Anti‐diabetic treatment aims to control glucose
homeostasis as tightly as possible in order to reduce these complications.
Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are a recent addition to the
anti‐diabetic treatment modalities, and have become widely accepted because of
their good efficacy, t...
Tổng số: 51
- 1
- 2
- 3
- 4
- 5
- 6